Your session is about to expire
← Back to Search
Pembrolizumab for Multiple Myeloma
Study Summary
This trial is testing pembrolizumab given with ixazomib citrate and dexamethasone to see if it is an effective treatment for relapsed multiple myeloma.
- Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In what contexts is Pembrolizumab commonly prescribed?
"Pembrolizumab is frequently used when tackling recurrent cervical cancer, but it may also be beneficial to those suffering from synovitis, refractory relapsed mediastinal large b-cell lymphoma and ophthalmia sympathetic."
What is the ultimate aim of this clinical research project?
"This medical trial will span two years and evaluate outcomes such as the overall response rate, incidence of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0., percentage with pembrolizumab added to ixazomib citrate and dexamethasone achieving a very good partial response (VGPR), complete response (CR) or stringent complete response (sCR), and survival time calculated using the method of Kaplan-Meier."
What is the cumulative enrollment for this experimental program?
"At this juncture, the trial is not actively searching for participants. It was first posted on June 19th 2018 and last updated October 19th 2022. If you are seeking clinical trials involving multiple myeloma, there are currently 807 active studies recruiting patients; similarly 1528 medical research projects require Pembrolizumab enrollees."
Has Pembrolizumab been accredited by the FDA?
"The risk posed by Pembrolizumab has been evaluated and rated as a 2, based on the evidence available from Phase 2 trials. This implies that while safety data is present, there is yet to be any supportive information in regards to efficacy."
Are there any remaining opportunities for people to join this clinical research?
"As of October 19th 2022, this trial is no longer recruiting. Initially posted on June 19th 2018, it was most recently updated four years later. Nevertheless, 807 studies that are accepting participants with multiple myeloma and 1528 trials for Pembrolizumab remain active in recruitment."
Share this study with friends
Copy Link
Messenger